Privacy preferences
Inderes uses cookies to provide a better user experience and a personalised service. By consenting to the use of cookies, we can develop an even better service and will be able to provide content that is interesting to you.
  • Forum
  • Premium
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Morning ReviewDaily market recap and key overnight highlights
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • PortfolioInderes model portfolio
    • FemmeBreaking barriers and building confidence in investing
  • Learn about investing
    • Analysis SchoolLearn how to read and understand stock analysis
    • Investing SchoolGuides and lessons to grow your investing knowledge
    • Portfolio buildersInvesting knowledge for every level, from first steps to advanced portfolio strategies.
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
    • Earnings SeasonCompare EPS estimates to reported results
    • Insider TransactionsTrack buying and selling activity by company insiders
    • Short SellingSee which listed companies have disclosed short interest
    • Virtual Analyst ChatAsk questions and get instant AI-powered investment insights
    • Compound Interest CalculatorSee how your savings grow with the power of compound interest.
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • Instagram
  • X (Twitter)
  • Tiktok
  • Linkedin
Get in touch
  • info@inderes.fi
  • +358 10 219 4690
  • Porkkalankatu 5
    00180 Helsinki
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Q&A
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Transcripts

Read transcripts of webcasts and audiocasts

Transcripts

Read transcripts of webcasts and audiocasts

All regions
Finland
Sweden
Denmark
Norway
Latest
Trending
Followed

Camurus, Audiocast, Q3'25

By Inderes11/6/2025, 1:00 PM
Camurus

Disclaimer: This is a machine-generated transcript and may contain inaccuracies.

Fredrik Tiberg
00:00 - 02:57

Third quarter earnings call. It's a beautiful autumn day here in Lund, Sweden, where we are broadcasting from. I will assume that you have read our forward-looking statements here. So the agenda for the call today is as follows. We start with third quarter highlights, move on to financial and commercial performance reviews, followed by an update on R&D. And then we'll finish off with key takeaways and Q&A. With me on the call today are Anders Vadsholt, Chief Financial Officer, and Richard Jameson, Chief Commercial Officer. During the quarter, Camurus delivered strong profitability, continued the progress of pipeline programs, and prepared for the launch of our next commercial product, starting here with some highlights. On the financial side, our quarterly revenues increased by 18% year on year, and 25% at constant exchange rate to 575 million SEK, driven by higher Brixadi royalties. Profitability remained strong, growing by 48% to 245 million SEK, increasing our cash position to 3.5 billion SEK. We maintained our profit guidance; however, due to the headwinds we have faced, we have lowered our full-year revenue guidance. The commercial performance in the quarter was mixed. You could say Buvidal sales in Europe slowed down temporarily, primarily due to ongoing funding issues, while Brixadi reported double-digit sales growth quarter on quarter. In parallel, we prepared for the launch of Oczyesa in the European markets. This has been progressing very well. On the R&D side, marketing approval for Oczyesa was received in the UK, and we also updated the NDA draft for submission. This is pending completion of an inspection of the contract manufacturer. We were also granted two new orphan drug designations for CAM2029 in autosomal dominant polycystic kidney disease, and in addition, the treatment was completed in the phase one trial of our monthly semaglutide formulation, CAM2056. Overall, the third quarter has presented both challenges and significant successful developments and progress. And with this, I leave the word over to Anders to review the financial performance of the quarter more in detail.

Anders Vadsholt
02:59 - 07:09

Third quarter earnings call. Fredrik. It's a pleasure to provide the first financial update after joining Camurus in July. I'm generally pleased with the financial performance in the third quarter. Camurus reported 567 million SEK in revenue for the quarter, reflecting an 8% increase compared to the same period last year. Year to date, the reported revenue is 1.8 billion, representing a 35-37% growth from previous years. Product sales reached 455 million, an increase of 8% compared to the same period last year, but a decline of 3% compared to the previous quarter. We have experienced stable in-market growth throughout the year, but the distribution model has caused some deviations in the timing of revenue recognition. Brixadi sales in the US generated 111 million in royalty income for the quarter, up 91% compared to the same period last year, and a 25% increase from the previous quarter. The company's profit before tax was 245 million SEK, reflecting a 43% profit margin for the quarter and a 48% increase in profit compared to the same period last year. The profit margin year to date is 45%. The profit after tax for the quarter was 193 million, representing an earnings per share after dilution of 3.9 SEK. Moving to the P&L, the company's gross margin was 93.1% for the quarter. Total operating expenditures were 298 million, a 2% reduction compared to the same period last year. The main components were an increase in our investment in marketing and distribution by 27% to 142 million SEK to support market penetration, expanding Buvidal into new markets, and building our US operation. The recruitment of the US sales force has been aligned with the new timelines for the launch of Oczyesa. Administrative expenses increased by 49% to support company growth and development, mainly in the US, reaching 40 million SEK compared to the same period last year. And R&D investments were 109 million, a reduction of 33% compared to the same period last year. This is mainly due to the completion of trials and the absence of clinical trial milestone payments in the SORENTO and POSITANO programs during the quarter. Looking at the cash flow for the quarter, Camurus increased its cash position by 167 million, mainly driven by operational activities, adding 221 million SEK and proceeds from the Employee Stock Option program. Adding 43 million in working capital investments decreased cash by 97 million, resulting in a net cash position of 3.5 billion, which is an increase of 28% compared to last year. Moving to the update of the 2025 financial guidance, despite positive developments in Brixadi and Buvidal, revenues do not meet our previous expectations and guidance for the full year. This is primarily due to Brixadi. US revenue is below the previous projections, and there is uncertainty about the timing of a sales milestone. In addition, we have seen continued delays in the allocation of committed governmental funding for the treatment in the UK. Importantly, our profitability has continued to develop positively with good financial discipline across the organization, and our planned US expansion has been aligned with the updated approval timeline for Oczyesa. As a consequence, our restated full year 2025 outlook is as follows. Our revenue guidance is lowered to 2.3 to 2.6 billion Swedish kronor, and profit before tax is unchanged in the range of 0.9 to 1.2 billion Swedish kronor. So nevertheless, Camurus ended the first quarter. Third quarter with a healthy financial position, promising outlook for continued growth, profitability, and pipeline progress. With that, I would like to hand over to Richard.

Richard Jameson
07:11 - 10:52

The profit after tax for the quarter was 193 million, representing an earnings per share after dilution of 3.9 SEK. Anders. I'll start with Camurus. Markets. So net sales for Buvidal in the quarter were 455 million SEK, up 8% year on year, or 15% at constant exchange rate versus Q2. Sales were down 3%, primarily due to the lower-than-expected orders in the UK, which also led us to reduce inventory levels. In contrast, underlying in-market sales grew 3% versus Q2 and are up 21% year to date, driven by maintained growth in Australia, Norway, France, and Spain as we continue to execute on our plans. While we saw flattening of growth in the UK and Germany due to two main factors, in the UK, there are ongoing delays in allocated funding reaching community clinics. However, growth began to accelerate in the criminal justice setting as allocated NHS funding for long-acting injectable buprenorphine treatment in prisons has become available. Resistance to uptake remains due to the ongoing remuneration of physicians based on daily visits. Year to date, market growth is positive at around 20% across markets, with the exception of Finland, where growth was in single digits due to the high penetration we have there. There continues to be high demand from patients and physicians for long-acting injectable buprenorphine, and we continue to support this through active programs that raise awareness of the benefits the product brings to patients and wider society. This, in turn, is increasing demand for wider accessibility and is expected to deliver renewed growth in 2026. So on the next slide, I share more detail of our ongoing strategy for improving patient access. We are continuing to grow the real-world evidence base and develop economic models that demonstrate the improved outcomes and the value that long-acting buprenorphine brings over daily treatments. The economic models, some of which are published on the left-hand side of the slide, clearly demonstrate the positive value of treatment, with Buvidal typically showing a more than three-fold return for governments. These data and models are a critical part of our initiatives to improve access through a government affairs program engaging a wide group of policy stakeholders who will benefit from improved access to these innovative treatment options. As a result of these programs, we are seeing growing demand in criminal justice settings and the need for community continuity of care upon release, alongside support to address funding in community settings. This has already resulted in some success, including the allocation and distribution of funding from the criminal justice setting in the UK that I mentioned earlier, and regional funding expansion in France. We also understand good progress is being made on alternative remuneration models in Germany that will address this key hurdle for Buvidal. The success of this activity is critical to expanding the use of Buvidal in these markets in 2026. Now moving across to the US, Brixadi had a strong quarter, as you've already heard, with royalties growing 25% compared to the previous quarter and 91% year on year. Brixadi continues to outgrow the market and has reached approximately a 30% share of the long-acting buprenorphine segment, which itself is growing 25% year on year. And for the first time, we achieved annualized sales of 1 billion USD in the US. The Brixadi represents a significant opportunity for future growth through penetration of the sublingual buprenorphine market, with an estimated 1.8 million patients in treatment and with further potential in the criminal justice setting. Brixadi has a clear and differentiated profile, and Braeburn is successfully navigating the challenges in the OUD treatment market. So overall, we remain optimistic about the prospects for Brixadi in the US and the potential for significant growth in the coming years. And on this, I'll hand back to Fredrik.

Fredrik Tiberg
10:54 - 21:19

Year to date, the market growth is positive around 20% across markets, with the exception of Finland, where growth was single digit due to the high penetration we have there. Richard. So, let's move over to a quick pipeline update. So starting with the progress of the Octreotide depot programs for acromegaly, gastroenteropancreatic neuroendocrine tumors (GEP-NET), and polycystic liver disease (PLD). As you know and have heard before, we have a large clinical program for CAM2029, which represents a major investment and future potential for Camurus in acromegaly. We have successfully completed the program, delivering positive results from two pivotal phase three trials, as well as a long-term extension study in GEP-NET. We advanced the SORENTO trial towards the important readout of the primary efficacy results in 2026. Finally, we recently received complete results. We recently completed the POSITANO study in PLD, also yielding positive results for the primary endpoint. I will start here with an update of the SORENTO study in Gep-net. This was recently discussed at a well-attended scientific symposium at the North American Neuroendocrine Tumor Society meeting in Austin, Texas, where it garnered significant attention among the participating physicians and other healthcare providers. The topic of the symposium was dose optimization of somatostatin receptor ligands, which is the efficacy-driving hypothesis behind the SORENTO trial. The chair of the symposium was Doctor Jennifer Chan, President of Neonates, and the presenter was Simron Singh from the University of Toronto. Who is the president-elect, now actually the President, of Neonates? Both are SORENTO study investigators and steering committee members. The conclusion of this discussion was that there are very high hopes and good prospects for SORENTO and CAM2029. Of course, providing positive outcomes. Patient recruitment in SORENTO was started already in Q4 2021, which means that the first enrolled patients have now been in treatment for about two years, in many cases without disease progression. The study was fully recruited at the end of 2023, as all patients have been assessed for about two years or longer. So far, the experiences from the trial are generally very positive in terms of patient feedback, and the projections for completing the randomized efficacy part of the trial have been extended based on the lower than predicted rates of progression-free survival events during the past few months. We recently completed a new analysis of the accrual rates in the study, and based on the trends, we have updated the projections for reaching the 194 events for the study to mid or second half of 2026. From a CAM2029 and study outcomes perspective, the adjustment should be positive while also extending the time to primary results. To put this in perspective, I would like to highlight the study design and patient population that is part of this SORENTO trial. So compared to previous studies of tumor progression, SORENTO is a randomized active controlled study with the primary objective to assess the superiority in progression-free survival for treatment with CAM2029 versus the standard of care with first-generation somatostatin receptor ligands. It is indeed the largest ever study of SRL performed in patients with neuroendocrine tumors, and this is an important point as the majority of the patients in SORENTO have advanced. Grade two or grade three neuroendocrine tumors at baseline, compared to no or minor portion of patients in the earlier tumor control trials. Pyramid and Clarinet. The progression-free survival for the blinded population in SORENTO should be viewed in the context of the study population, which makes us optimistic about the study prospects. Moving over to PLD during the quarter, we continued analyzing data from the POSITANO trial in preparation for an end of Phase Two meeting with the FDA, planned for early next year. Furthermore, CAM2029 was granted orphan drug designation for autosomal dominant polycystic kidney disease (ADPKD), both in the US and EU. During the period, this points to the high unmet medical need in this indication. Importantly, this can also expand future orphan drug exclusivity to PLD arising from ADPKD. So that is significant progress in itself. Finishing off with the acromegaly indication, Oczyesa has now been granted market authorization for the treatment of acromegaly in both the EU and the UK. For the US, the NDA has been updated during the quarter and is ready for resubmission as soon as we have received the green light from an inspection at the contract manufacturer. Please remember that there was nothing in the CRL from the FDA that was related to the product itself or its clinical or safety data. Based on our plans for resubmission, we expect a new PDUFA date and a potential US launch of Oczyesa in the first half of 2026, which will of course be an important event for us. In parallel, we are preparing for the launch of Oczyesa in Europe. The first monthly subcutaneous octreotide medication on the market enables convenient self-administration for patients and enhanced octreotide plasma exposure. The European launch has now been initiated in the wave one countries with an estimated 3 to 5,000 acromegaly patients currently treated with first-generation, long-acting somatostatin receptor ligands. The response to the Oczyesa profile from physicians and patients has so far been very encouraging, with a positive view on both the clinical data and market research that we have performed in the area show a high willingness to switch to Oczyesa from current somatostatin receptor ligands. In addition to this, we have also received positive initial feedback from payers. So, as you may have seen from the announcement earlier this week on Monday, Oczyesa has now been launched in Germany as the first country in Europe and globally, and our medical affairs and sales team are now out in the field. Germany represents a substantial opportunity, with about 2,000 patients currently in treatment with first-generation somatostatin receptor ligands and with an annual sales potential of over €50 million. A recent physician survey suggests that about 30 to 60% of these patients are initially considered suitable for switching to Oczyesa. Obviously, GEP-NET represents a much larger opportunity. However, acromegaly is, of course, a great starting point here. Alongside the advances of the CAM2029 program. We have also completed treatment of the last patient in the Phase One study of our monthly semaglutide formulation, CAM2056, based on our FluidCrystal technology. We now expect to provide top-line results this month with a focus on tolerability and, of course, importantly, efficacy indicators such as body weight and HbA1c. In addition, we progressed our strategic partnership with Eli Lilly for the development and commercialization of long-acting incretins in the cardiometabolic area, including GLP-1, GIP dual agonists, and GLP-1, GIP, glucagon triple agonists. We are naturally very excited about progressing this collaboration. So with this, I think it's time to finish off with some key takeaways of the quarter. In summary, we had a good quarter, as you have heard, though not without challenges. However, we made significant advances, progressing and expanding our business, delivering strong profitability and cash flow, and maintaining stable Buvidal sales in Europe and Australia. I think our team is doing an excellent job also with regards to the future development in the market. Notably, Brixadi had another strong quarter in the US, surpassing the rest of the market. In addition, for Oczyesa in acromegaly, we received UK approval and have prepared for the launch in Germany. And also, as I mentioned recently here, we advanced our promising long-acting Incretin pipeline. With this final note, I think it's time now to move over to Q&A. So please take over the call.

Operator
21:20 - 21:26

Thanks, Fredrik. The first question is from Victor Zumbach from Nordea. Please go ahead. Victor, your line is open.

Unknown 1
21:29 - 21:56

So, as you may have seen from the announcement earlier this week on Monday, Oczyesa has now been launched in Germany as the first country in Europe and globally, and our medical affairs and sales team are now out in the field. Hi, and thanks for taking my questions. So I had a question first. Buvidal. I just wondered if you could provide any more details about when you expect funding to be released to clinics. And when the market could turn around in the UK? I'm just trying to get a feel for if this could spill over into Q4 as well or into early 2026, or how we should model this impact. Thank you.

Fredrik Tiberg
21:57 - 22:00

Yeah, I will leave that over to Richard to handle.

Richard Jameson
22:01 - 22:23

Yes, I mean, our funding is coming in dribs and drabs. There are some areas that are receiving funding now, while others are less so. I can't guess what the government would do, but we hopefully will see some advances in Q4 and then moving into 2026 as well. On that. I mean, it is growing the U.K. market. We are getting more patients. It's just slower than we anticipated.

Unknown 1
22:25 - 22:38

Thank you. Thanks. I also had a question, as you have launched Oczyesa now in Germany, could you comment on how it's priced versus the other injectable depot formulations on the market? Thank you.

Fredrik Tiberg
22:39 - 22:55

Yes. I think you could estimate that it's priced at the high end of the Sandostatin reference product. So, okay, just so it's clear, I think its official price now.

Richard Jameson
22:56 - 22:57

It's just under 3,000.

Fredrik Tiberg
22:57 - 23:03

Yes. Just under €3,000 per dose.

Unknown 1
23:03 - 23:05

Yes. Thank you. Thank you very much. That's all for me.

Fredrik Tiberg
23:14 - 23:17

Next. Hello.

Unknown 2
23:18 - 23:19

Hi. Can you hear me?

Fredrik Tiberg
23:21 - 23:22

Yes, we hear you.

Unknown 2
23:23 - 23:44

Cool. A couple of questions on my end. The first one is for Buvidal in Europe. How many net patient additions were there in Q3? And are there any additional markets that recently came into play? For example, considering Portugal, can they support future growth while the issues in the UK and Germany persist?

Fredrik Tiberg
23:45 - 23:55

Yes, certainly. I mean, we reported the number of patients to be 67,000. But Richard, maybe you can comment on the growth in the additional markets, particularly in Spain.

Richard Jameson
23:55 - 24:13

And yes, I mean, everybody makes a contribution. We grew by 2,000 patients between quarters this time; Portugal is yet to really come on board. It's early days in that market. So we're waiting to see that. But yes, they will provide an opportunity for us as we move forward to grow the number of patients in treatment.

Fredrik Tiberg
24:13 - 24:41

We're seeing positive trends also in Spain, where we are recognizing significant potential. And of course, we have further countries, including the northern European region. Maybe this should also be put into the context of the dynamics of other movements in the Nordic markets and elsewhere. But it looks like there is good growth potential.

Unknown 2
24:44 - 25:05

A couple of questions on my end. A couple of questions on my end. A couple of questions on my end. And then maybe another question on Brixadi in the US. At the last update, I think it was around Q4 last year. The numbers showed roughly a 25% market share for Brixadi in the markets. Now it stands at 30%. Is this the market share of new patients switching from sublingual buprenorphine to Eli?

Fredrik Tiberg
25:06 - 25:33

I think the main component, as we have discussed for quite some time, is that most patients are transitioning from sublingual buprenorphine, of course. Depending on the relative growth in that segment, this will of course impact the market share between different products. So, I would say the majority of the share is coming straight from sublingual.

Unknown 2
25:35 - 25:45

A couple of questions on my end. I mean, the reason why I'm asking this is last week In Vivo reported a 75% market share. So, we're just wondering on which metric you base this 30% market share.

Fredrik Tiberg
25:46 - 26:06

So we have used several different metrics, we should say, or different data sources. And all of them converge at 30%. And that includes both public sources and also other sources that we have access to.

Unknown 2
26:09 - 26:11

Okay. Thank you very much. That's awful.

Operator
26:15 - 26:23

Sorry. The next question is from Richard Romanus from Reddit. Please go ahead. Please go ahead.

Unknown 3
26:23 - 27:17

Good afternoon. Yes, I had two questions regarding the guidance for this quarter. So, I'll just read both questions straight away. In your Q3 report, you guided for around 650 million R&D costs in 2025, and also this was addressed in your Q3 report. Is this because you expect costs to be lower this year? Just because you overestimated costs or because some costs will be postponed into 2026? My second question is, you lowered the guidance to say implicitly from Braeburn as you don't expect the milestone, which I assume is revenue-based. Is that due to strong US competition, other market dynamics, or both?

Operator
27:20 - 27:20

Okay.

Anders Vadsholt
27:21 - 27:49

So we're just wondering on which metric you base this 30% market share. So. So, uh, shortly. So, you know, we're not driving a project ahead of our capabilities as, of course, there will be some delays. But there have also been a number of savings in the R&D department. We're doing a tech transfer and so on. So, it is due to cost reductions. And then some of the costs will be postponed to 2026. So it's a mixed situation here, but it will be lower for the year.

Unknown 3
27:55 - 27:57

Okay. That's good to hear.

Fredrik Tiberg
28:02 - 28:05

Could you please repeat, I missed the second question. Sorry for not answering that.

Unknown 3
28:08 - 28:28

Yeah, sure. No problem. Um. Implicitly, you guided for lower revenue from Braeburn since you no longer assume a milestone payment, which I assume is related to revenues. Is that because of strong US competition or just because of market dynamics?

Fredrik Tiberg
28:29 - 28:59

I think it's mainly market dynamics. I mean, we had very high expectations for the year and those have gradually come down. But I think the good news is that we have seen very good recovery here, and especially now, a consistent recovery. But in total, this has led to the milestone being at risk, which of course it was not in the early phase of the assessment.

Unknown 3
29:03 - 29:07

That's good to hear. That's where most of my questions lie. That's good to hear.

Fredrik Tiberg
29:07 - 29:08

That's good to hear.

Operator
29:09 - 29:13

The next question is from Sean Harmer from Jefferies. Please go ahead.

Fredrik Tiberg
29:16 - 29:17

Hello, Sean.

Operator
29:18 - 29:25

I think actually it's Romeo O'Connor. Oh, yes. Sean. Sean, if you can queue up again.

Unknown 4
29:27 - 29:51

That's good to hear. Hello, everybody. Hello. I have one question. I was wondering if you could provide more color on your manufacturing expansion efforts in the US. I know you're planning further investments to deploy US operations for acromegaly. I'm just wondering what your strategy is for GEP-NET next year and what your sales force will look like there. Thank you.

Fredrik Tiberg
29:53 - 30:24

Yes. In terms of manufacturing, we discussed this last quarter. All of those processes are advancing perfectly. Obviously, we have our current sources, but we need to secure future supplies, especially when Gep-net comes up. So, that's an important part of the further development of Gep-net. And that is progressing perfectly according to plans. So that's progressing well. Yes. Positive.

Unknown 4
30:24 - 30:44

And then. And then just maybe one more quickly. I was just wondering if you could share a bit on your future outlook for the Australian market with Buvidal, because now you've reached an 80% share. I think of the market. Do you think this is reaching a plateau or do you see future growth here?

Fredrik Tiberg
30:45 - 30:45

Richard.

Richard Jameson
30:46 - 31:11

I know you're planning further investments to deploy US operations for acromegaly. I mean, Australia continues to grow well. We have about 30% share of the total market now. And as you said, we have above 80% in the long-acting segment. We still see that demand in Australia. We still see it growing. There are many people still on sublingual therapies who are interested in transitioning. And of course, methadone is a large segment as well. And we're seeing increasing numbers moving across from methadone because of the advantages long-acting treatments bring. So, we anticipate continued growth in Australia.

Unknown 4
31:13 - 31:14

I know you're planning further investments to deploy US operations for acromegaly. Clear. Thank you.

Operator
31:16 - 31:19

Now we have Sean Harmer from Jefferies. Please go ahead.

Fredrik Tiberg
31:20 - 31:21

Hello, Sean.

Sean Harmer
31:21 - 31:47

Hi there. Thanks. Hi, Fredrik. Just two questions from me. I'll take them one at a time. So, on the SORENTO readout, we know this has been pushed to late 2026. It makes sense that this is because of the time to recruit events, but are there any concerns that the control arm may be outperforming, such as, for example, when the Evobrutinib phase three study readout on Aubagio surprisingly outperformed?

Fredrik Tiberg
31:49 - 32:48

Well, I mean, you can never provide guarantees on these things. So, in terms of this, we are using literature reference data and are trying to compensate for populations and population characteristics, and so forth. There is nothing new that has happened in terms of the standard of care changing in terms of treatment changes and so forth. So, I think we should, you know this. This should not be the case. But you can never be 100% sure. But I think our view on this, and that's also our physicians' input, is that, you know, there have not been any material changes to the treatment regimen for the standard of care. So, it's about trying to understand the different data sources. And I think we have a good indication.

Sean Harmer
32:50 - 33:06

Understood. Thank you. And then for my second question, could you tell us what was communicated with respect to the Criminal Justice Channel and the dynamics that occurred during Q3 on both the state and federal side? And then what would it look like for Q4.

Fredrik Tiberg
33:08 - 33:33

Well, I mean, that leaves me with, I'm sorry, because of the competitive situation and also because of our contractual situation, I'm not able to go into any details. On this note at this moment, I am not able to provide further details. Sean, I would, of course, want to, but I cannot fill you in on this.

Sean Harmer
33:35 - 33:37

No. That's fair. Thank you. Fredrik.

Fredrik Tiberg
33:37 - 33:38

Thank you.

Operator
33:40 - 33:45

The next question is from George Bjarke at ABG. Go ahead. George.

Unknown 2
33:47 - 33:51

Hi, George. Thank you for taking my questions.

Unknown 5
33:51 - 34:36

I have a couple. So, first, I was wondering whether you or Braeburn Pharmaceuticals have seen any price pressure for Buvidal or Brixadi lately. And secondly, your competitor Indivior. For example, at the Q3 reporting last week, they highlighted that Sublocade has a unique offering in the long-acting release category in terms of rapid induction, i.e. a second monthly dose injection after one week. So, of course, Indivior has a history of quite aggressive marketing. So I'm curious if you are able to comment on whether or not you think this is a significant distinguishing factor versus Brixadi, considering Brixadi allows for weekly initiation with weekly dose injections. Thank you.

Fredrik Tiberg
34:37 - 36:06

Thank you so much. Well, to the first question about price, I don't think we have heard about any price pressure in the US. I mean, obviously, the whole system with its pricing is an increasingly important component. However, I haven't heard of anything specific there or anything that is concerning to us regarding the rapid initiation with Indivior's product. I prefer not to make judgments against a colleague in the market here. I think, you know, it probably has some advantages for them. I think we have a very good treatment regimen as it is. We have, you know, the transfer doses from sublingual, which is the most important market. Additionally, we offer the weekly start. So, we have, you know, we have all of this under control. A big study was conducted in emergency centers in the US with over 2000 patients, using the weekly start as a very successful measure to transition patients from in-hospital treatment to outpatient treatment. Additionally, it's used very regularly in the system. Do you have anything further to add, Richard?

Richard Jameson
36:06 - 36:24

Yeah. To add to that, I mean some of the feedback from some of the research we've seen from various groups is that patients like starting with weekly doses, because they want to understand what it feels like to be on a long-acting treatment before they commit fully to a monthly regimen. So I think the patient's preference is for a monthly initiation rather than a weekly one. And our experience in Europe shows that.

Fredrik Tiberg
36:24 - 36:59

I think mostly. Yes, and most importantly, we still see that our partner appears to be doing a good job in the US. We are progressing. Regarding CAM2029, I should mention that we're progressing Brixadi nicely in the US based on our competitive profile. And I think that holds a lot of advantages compared to other products in the market. So. But thank you for the question.

Operator
37:05 - 37:09

So I think the patient preference is for a monthly over a weekly initiation. And the next question is from Susannah Quek from Handelsbanken.

Susannah Quek
37:12 - 37:48

Hello, Susannah here. Can I ask another question about Buvidal? So you have your target for 2027 of reaching 100,000 patients, with the last two quarters adding 2,000 patients. You need to substantially accelerate the net addition to reach that going forward. Perhaps you could comment on how you are planning to address this. And then also, is that possible in the markets that you currently have, or will you need to address the regions where we've had budget constraints differently?

Fredrik Tiberg
37:49 - 38:06

Yes. First, we still retain our vision for 2027, also in regards to the 100,000 patients. Obviously, there are challenges and opportunities. Maybe, Richard, you want to go into your thinking around this.

Richard Jameson
38:06 - 38:38

So I think the patient preference is for a monthly or a weekly initiation. I mean, it's not necessarily a linear approach as we create successful arguments to increase access. We can see acceleration there. And we have a number of ongoing processes in discussions with various groups that could still prove fruitful. And our ambition is still achievable. And I think we have to remember that we still have relatively low penetration in this market at about 10% of patients. So there's still plenty of opportunity to grow the business. And we can, if we resolve the funding issues and the hurdles we faced, which we're on track to do.

Fredrik Tiberg
38:39 - 39:05

Adding to that, obviously, we have great teams working in various areas, ranging from government affairs to direct contacts with medical professionals and so forth. And we generally have a very positive outlook. As Richard says, it will not be a linear curve up to the goal, and it will require a lot of hard work. But we retain our vision, and we are working hard to achieve it.

Susannah Quek
39:08 - 39:30

Very good. And then a follow-up on the Eli Lilly deal. In the initial press release, you didn't mention anything regarding Amylin, but there was an opportunity to expand. Can you maybe just give us a little bit more on what progress has been made recently, and how you think about other incretins?

Fredrik Tiberg
39:31 - 40:04

I can't give you any update because it's outside my remit, so to speak. But, yeah, I mean, obviously they have an option to Amylin and usually an option has a time limitation coupled to it. So that's one of the components of our collaboration, which I think you can say is progressing very well right now. But I can't give you any details on that. Beyond those two comments.

Susannah Quek
40:06 - 40:08

And we generally have a very positive feel. Thank you very much.

Fredrik Tiberg
40:08 - 40:09

Thank you, Susanne.

Operator
40:10 - 40:13

The next one is from Dan from Pareto Securities.

Unknown 6
40:17 - 40:44

Hello. And that's just one more question. That is regarding 2056 as well. If you can share just some more details on what you're expecting from the data readout this month and what you will be able to share, in terms of the details of the data. And we generally have a very positive feel. And we generally have a very positive feel.

Fredrik Tiberg
40:46 - 42:28

And we generally have a very positive outlook. Yes. First of all, I think it's important to know the study design. So basically the study design has one part which is a randomized component, versus semaglutide. So, the monthly versus the weekly. And then, there is a second part of the study, which is essentially a dose escalation part. We're going from low to high concentrations to examine the effects of very high concentrations. So, obviously, we will report comparative data focusing on the tolerability profile, which is important, as well as weight and PD readouts in terms of HbA1c and so forth. The traditional measures will most likely be provided in a press release with key data points. And then, later on, we'll likely follow up with more detailed information about the product results. So I think that's the order of them. But what is unique with this study is, of course, that we have an active comparator. I think it's not that usual that you go into a phase one study with an active comparator. So it will be an interesting readout from the study with, I think, clear potential to demonstrate something of relevance. That's as far as we get.

Unknown 6
42:29 - 42:30

So obviously, we will report comparative data, focusing on the tolerability profile, which is important, weight, and PD readouts in terms of HbA1c and so forth.

Operator
42:32 - 42:35

We have a follow-up from Sean from Jefferies as well.

Fredrik Tiberg
42:37 - 42:37

Sean.

Sean Harmer
42:39 - 42:54

Hey, just one more from me really quickly. Can we expect CAM20256 to be press released this month then? And could you just discuss the level of detail that will be included in the release? I know it's only phase one, but any sort of detail would help. So obviously, we will report comparative data, focusing on the tolerability profile, important weight, and PD readouts in terms of HbA1c and so forth.

Fredrik Tiberg
42:55 - 43:29

Yeah, I mean, absolutely, our intention is according to the current timelines, to be able to release a press statement this month. And regarding the data, I mean, we will. I think you can anticipate about the same level of detail as you see from other pharmaceutical companies working in the space for a phase one trial or early phase two trial. So I think you should expect approximately that level of detail.

Sean Harmer
43:31 - 43:31

Thank you so much.

Fredrik Tiberg
43:32 - 43:33

So obviously, we will report comparative data focusing on the tolerability profile, weight, and PD readouts in terms of HbA1c and so forth. Thank you.

Operator
43:34 - 43:40

There are no more questions at this time. So I hand the word back to you, Fredrik and Richard, for closing comments.

Fredrik Tiberg
43:41 - 44:05

So obviously, we will report comparative data focusing on the tolerability profile, which is important, along with weight and PD readouts in terms of HbA1c and so forth. So obviously, we will report comparative data focusing on the tolerability profile, which is an important aspect along with weight and PD readouts in terms of HbA1c and so forth. And I just want to say this. Of course. We thank you very much for joining this call. It's a pleasure to have interest from you all and engaging questions. And I look forward to meeting you all on the road or at our next call in Q4, the Q4 report. And with that said, thank you again. And we can close the call.

Continue to the webcast
Revenio Group Oyj, Q3'26
Language: English11/12/2026, 1:00 PM
Jukka Kainulainen Good afternoon, and welcome to the Revenio Group Corporation Q3 Earnings Call. My name is Jouni Toijala. I am the CEO. And then, again today we have Jukka Kainulainen, our CFO, on th…
Kamux, Q3'26
Language: English11/12/2026, 9:00 AM
Katerina Heterant Good morning. Welcome to the Kamux Q3 results presentation. My name is Katerina Heterant and I am Head of Investor Relations at Kamux. Today we shall go through the Q3 results presen…
Koskisen, Webcast, Q3'26
Language: Finnish11/12/2026, 8:00 AM
Jukka Pahta Hyvää huomenta ja tervetuloa tähän osavuosikatsaustilaisuuteen! Koskisen tammi–syyskuun osavuosikatsaustilaisuuteen lähdetään otsikolla: Koskisen liikevaihdon kasvu jatkui. Kohonneet kusta…
Reaktor, Q3'26
Language: Finnish11/11/2026, 9:00 AM
Pekka Horo Oikein hyvää aamupäivää kaikille ja tervetuloa tähän meidän webcastiimme. Olen Pekka Horo, Reaktorin toimitusjohtaja, ja kanssani täällä on tänään Antti Akkanen, joka aloitti lokakuussa Rea…
Savox, Q3'26
Language: English11/10/2026, 11:00 AM
Paulina Tanila Our speakers today are CEO Jerry Kettunen and CFO Juha Järvi. Jerry will give an overview of Savox as a company and go through the highlights of the quarter. After that, Juha will conti…
Raisio Oyj, Webcast, Q3'26
Language: Finnish11/10/2026, 10:00 AM
Elli Siltala Hyvää marraskuista päivää Raisiosta! Ja tervetuloa Raision tammi-syyskuun 2026 osavuosikatsauksen webcastiin! Pahoittelut pienistä teknisistä haasteista, mitä meillä oli tässä alussa. Min…
Mandatum Oyj, Audiocast, Q3'26
Language: English11/10/2026, 9:00 AM
Lotta Borgström Good morning, everyone, and welcome to the Mandatum Q3 2026 audiocast. My name is Lotta Borgström from Investor Relations. Joining me today are our CEO, Petri Niemisvirta, and our CFO,…
Solar foods Go-to-market Update
Language: English11/9/2026, 12:00 PM
Maria Hello everyone, and welcome to the Solar Foods go-to-market update. My name is Maria and I'm here today with our CEO, Rami Jokela, and CFO and Deputy CEO, Ilkka Saura. Also with us today is Heli…
Outokumpu, Webcast, Q3'26
Language: English11/6/2026, 12:30 PM
Johan Welcome to the third quarter results webcast. I am responsible for investor relations. We will start with the presentation from our CEO, Kati ter Horst, and our CFO, Marc-Simon Schaar. After the…
Endomines, Webcast, Q3'26
Language: English11/5/2026, 1:00 PM
Andy Turpin Hello, everyone, and welcome to Endomines' third-quarter results webcast. Thanks for joining us today. My name is Andy Turpin and I am the Chief Communications Officer here at Endomines. A…
Lemonsoft Oyj, Q3'26 webcast
Language: English11/5/2026, 11:00 AM
Unknown 1 Welcome to the Lemonsoft Q3 results presentation. We will start with the presentation from CEO Alpo Luostarinen, followed by the Q&A. You can send your questions throughout the event via the…
Enersense, Webcast, Q3'26
Language: English11/5/2026, 10:30 AM
Liisa Tamminen Hello and welcome to the Enersense Q3 2026 results webcast. My name is Liisa Tamminen from Enersense Investor Relations. And with me here I have our CEO, Kari Sundbäck, and CFO, Jan-Elo…
Sitowise, Q3'26
Language: English11/5/2026, 10:00 AM
Mari Reponen Good day everyone, and welcome to the Sitowise Q3 2026 results audiocast. My name is Mari Reponen, and I am responsible for strategy and IR here at Sitowise. And today with me are our act…
Orthex, Webcast, Q3'26
Language: English11/5/2026, 9:00 AM
Alexander Rosenlew Good morning and welcome to the Orthex Interim Report. My name is Alexander Rosenlew and with me I have Saara Mäkelä, CFO, and Hanna Kukkonen, our CMSO. We will take you through the…
Suominen Oyj, Q3'26
Language: English11/5/2026, 8:30 AM
Anni Luoma Good morning, everyone, and welcome to the Suominen Q3 webcast. My name is Anni Luoma. I am the Manager of External Communications and Investor Relations at Suominen. Here with me are our P…
Lumo, Webcast, Q3'26
Language: English11/5/2026, 8:00 AM
Niina Saarto Good morning, all. Welcome. This is Lumo Homes plc's third quarter result webcast. I am Niina Saarto from Treasury and Investor Relations. Today I have two gentlemen here with me, namely…
CapMan, Webcast, Q3'26
Language: English11/5/2026, 7:30 AM
Charlotte Good morning and welcome to this presentation of CapMan. Q3 2026 interim report. Presenting today we have Pia Kåll, CEO of CapMan. And after the presentation, we will have a Q&A session. You…
Marimekko, Webcast, Q3'26
Language: English11/4/2026, 12:00 PM
Anna Good afternoon. My name is Anna and I am the IRO of Marimekko. It is my pleasure to welcome you to our Q3 webcast. With me, I have our president and CEO, Tiina Alahuhta, who will walk you through…
Administer, Webcast, Q3'26
Language: Finnish11/4/2026, 9:00 AM
Kimmo Herranen Welcome to the Administer Q3 2026 interim report. Results. Meillä on se alkaa. I am Kimmo Herranen. Kalle Lehtonen. Also. Kaarina og. Yelken. Kalle Lehtonen En el coco. Madan. Parannus.…
Kempower, Webcast, Q3'26
Language: English11/4/2026, 8:30 AM
Unknown 1 Powering the planet. Kempower. We charge our planet for the better. By powering the electric movement. We enable quick and scalable EV charging solutions for everyone and everywhere. We ma…